Prevnar 13

also known as PCV-13 · 13-valent pneumococcal conjugate vaccine · Prevenar13 · Prevnar · Prevenar · 13vPnC · 7 valent pneumococcal conjugate vaccine · PCV7 · +38 more

Vaccine

Developed for: pneumococcal infection · HIV infectious disease · pneumonia · diphtheria · meningococcal infection · plasma cell myeloma · poliomyelitis · tetanus
+26 more
· meningitis · pertussis · hepatitis B virus infection · streptococcal pneumonia · disease related to solid organ transplantation · haemophilus infectious disease · otitis media · asthma · bacterial infectious disease · infectious disease · ataxia telangiectasia · bacterial pneumonia · chronic obstructive pulmonary disease · disease related to hematopoietic stem cell transplant · end stage renal failure · hepatocellular carcinoma · idiopathic severe pneumococcemia · infectious disease with sepsis · intrahepatic cholangiocarcinoma · nasopharyngeal disorder · respiratory tract infectious disorder · streptococcal infection · type 1 diabetes mellitus · acute lymphoblastic leukemia · chronic kidney disease · selective IgG immunodeficiency
Investigated by: Pfizer · Wyeth is now a wholly owned subsidiary of Pfizer · GlaxoSmithKline · Sanofi Pasteur, a Sanofi Company · National Institute of Allergy and Infectious Diseases (NIAID) · University of Oxford
+136 more
· Assistance Publique - Hôpitaux de Paris · Centers for Disease Control and Prevention · Merck Sharp & Dohme LLC · National Cancer Institute (NCI) · URC-CIC Paris Descartes Necker Cochin · Mayo Clinic · University College, London · Aghia Sophia Children's Hospital of Athens · Beijing Center for Disease Control and Prevention · Beijing Minhai Biotechnology Co., Ltd · Bill and Melinda Gates Foundation · CIC 1417 Cochin-Pasteur · EUCLID Clinical Trial Platform · Emory University · H. Lee Moffitt Cancer Center and Research Institute · Helsinki University Central Hospital · Hôpital Cochin · London School of Hygiene and Tropical Medicine · Menzies School of Health Research · Murdoch Childrens Research Institute · National Health and Medical Research Council, Australia · Novartis Vaccines · Papua New Guinea Institute of Medical Research · Public Health England · Shanghai Reinovax Biologics Co.,LTD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · The University of Western Australia · University Health Network, Toronto · VA Office of Research and Development · Wellcome Trust · ANRS, Emerging Infectious Diseases · AZ Sint-Jan AV · AbbVie · Aduro Biotech, Inc. · Agence de Médecine Préventive, France · Alaska Native Tribal Health Consortium · Alberta Children's Hospital · BUGS Bioscience London Bioscience Innovation Centre 2 Royal College Street London · Bayer · Beijing Municipal Health Bureau · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Belarusian State Medical University · CIHR Canadian HIV Trials Network · Canadian Immunization Research Network · Canadian Institutes of Health Research (CIHR) · Celgene Corporation · Centers for Disease Control and Prevention, China · Children's Hospital Medical Center, Cincinnati · Duke University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Fondo de Investigacion Sanitaria · German-Jordanian University · GlaxoSmithKline · Great Ormond Street Hospital for Children NHS Foundation Trust · Groupe Français d'Etude des Vascularites (GFEV) · Heinrich-Heine University, Duesseldorf · Henry M. Jackson Foundation for the Advancement of Military Medicine · Hospital Son Llatzer · Hospital Universitari Son Dureta · I-REIVAC Innovative Clinical Research Network In Vaccinology · IWK Health Centre · Infectious Diseases Clinical Research Program · Insituto Adolfo Lutz · Institut Pasteur · Institute of Child Health · Janssen Research & Development, LLC · Jena University Hospital · Jennifer Woyach · KEMRI-Wellcome Trust Collaborative Research Program · Kaiser Permanente · Kamuzu University of Health Sciences · Karolinska University Hospital · King Chulalongkorn Memorial Hospital · King Saud University · all 142 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Prevenar	—	2001-02-02	europa.eu ↗

Trials 170 · started per year

today

EU approved 2001

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT03802994	Nov 2018 → Feb 2020	—	VA Office of Research and Development	Terminated	No outcome recorded
Phase 0	NCT03039491	Sep 2015 → Mar 2020	lipodystrophy	Medical University of South Carolina	Completed	No outcome recorded
Phase 111 trials
Phase 1	NCT07019909	Jul 2025 → Jan 2026	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 1	NCT06675032	Apr 2024 → May 2025 overdue	pneumococcal infection	Shanghai Reinovax Biologics Co.,LTD	Active not recruiting	No outcome recorded
Phase 1	NCT05092386	Jan 2023 → May 2024	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05489328	Aug → Oct 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 1	NCT05155579	May 2022 → May 2025	malaria	University of Oxford	Completed	No outcome recorded
Phase 1	NCT02955160	Nov 2016 → Aug 2017	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 1	NCT02892812	Sep → Nov 2016	pneumococcal infection	LG Life Sciences	Completed	No outcome recorded
Phase 1	NCT01531322	Oct 2011 → Jan 2012	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 1	NCT00488826	Oct 2005 → May 2007	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 1	NCT00164411	Jan 2004 → Mar 2005	pneumococcal infection	Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 1	NCT00153543	May 2002 → Jun 2003	pneumococcal infection	Centers for Disease Control and Prevention	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT06703203	Jul → Aug 2025	—	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1/2	NCT03942328	Sep 2019 → May 2030 expected	hepatocellular carcinoma, intrahepatic cholangiocarcinoma	Mayo Clinic	Recruiting	No outcome recorded
Phase 1/2	NCT03819049	Jun 2019 → Jun 2021	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1/2	NCT00900978	May 2009 → Aug 2010	pneumococcal infection	German-Jordanian University	Unknown	No outcome recorded
Phase 1/2	NCT00566098	Nov 2007 → Jun 2014	plasma cell myeloma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 1/2	NCT00137605	Sep 2004 → Oct 2007	pneumococcal infection	CIHR Canadian HIV Trials Network	Completed	No outcome recorded
Phase 1/2	NCT00169234	May 2003 → Feb 2005	pneumonia	Kaiser Permanente	Completed	No outcome recorded
Phase 231 trials
Phase 2	NCT07286370	Apr 2026 → Apr 2028 expected	salmonellosis	GlaxoSmithKline	Recruiting	No outcome recorded
Phase 2	NCT07333352	Sep 2025 → Jul 2027 expected	pneumococcal infection	Shanghai Reinovax Biologics Co.,LTD	Recruiting	No outcome recorded
Phase 2	NCT05412030	Jun 2022 → Sep 2025	streptococcal pneumonia	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT04745559	Feb 2021 → Jul 2025 overdue	follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma	H. Lee Moffitt Cancer Center and Research Institute	Active not recruiting	No outcome recorded
Phase 2	NCT03376477	Sep 2019 → Jan 2024	plasma cell myeloma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 2	NCT03873727	Aug 2019 → May 2022	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT03550313	Jun 2018 → Nov 2020	pneumococcal infection	Pfizer	Terminated	No outcome recorded
Phase 2	NCT03069703	Feb 2018 → Nov 2020	pneumococcal infection	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02518555	Jan 2016 → Dec 2025	chronic lymphocytic leukemia/small lymphocytic lymphoma	Jennifer Woyach	Completed	No outcome recorded
Phase 2	NCT02482636	Aug 2015 → Nov 2017	infectious disease	University of Oxford	Completed	No outcome recorded
Phase 2	NCT02309515	Jun 2015 → Apr 2017	chronic lymphocytic leukemia/small lymphocytic lymphoma	Mayo Clinic	Terminated	No outcome recorded
Phase 2	NCT02255227	Apr 2015 → Aug 2019	inflammatory bowel disease, pneumococcal infection	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 2	NCT02052154	Mar 2014 → Jul 2016	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT02049138	Jan 2014 → Jul 2021	rheumatoid arthritis	AbbVie	Completed	No outcome recorded
Phase 2	NCT02274415	Sep 2013 → Sep 2017	pneumococcal infection, sickle cell disease	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01732198	Mar 2013 → Jan 2014	infectious disease	Nuron Biotech Inc.	Unknown	No outcome recorded
Phase 2	NCT01654263	Oct 2012 → Aug 2015	pneumococcal infection	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT01339000	Apr 2011 → Apr 2016	breast cancer, colon carcinoma, urinary bladder cancer	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT00824850	Jan → Sep 2010	—	Pfizer	Completed	No outcome recorded
Phase 2	NCT01049035	Dec 2009 → Feb 2012	meningitis, meningococcal infection	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT00721396	Aug 2008 → Jul 2010	meningococcal infection	Novartis Vaccines	Completed	No outcome recorded
Phase 2	NCT00505063	Jul 2007 → Jun 2025	childhood malignant neoplasm	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT00327522	Jun 2006 → ?	pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00338351	Apr → Oct 2006	hepatitis A virus infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00170612	Nov 2005 → Jan 2008	pneumococcal infection	University of Melbourne	Completed	No outcome recorded
Phase 2	NCT00269672	Sep 2005 → Feb 2007	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 2	NCT00219401	May 2005 → May 2009	meningitis, otitis media, pneumonia	Papua New Guinea Institute of Medical Research	Completed	No outcome recorded
Phase 2	NCT00323557	Jun 2004 → May 2011	leukemia	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00197821	Jan 2004 → Dec 2008	pneumococcal infection	Public Health England	Completed	No outcome recorded
Phase 2	NCT00148824	Feb 2003 → Jan 2006	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT01443117	? → Aug 2014	HIV infectious disease, pneumococcal infection	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT03384589	Aug 2018 → Mar 2023	idiopathic severe pneumococcemia, pneumococcal infection	University of British Columbia	Completed	No outcome recorded
Phase 2/3	NCT03098628	Mar 2017 → Jun 2020	—	Murdoch Childrens Research Institute	Completed	No outcome recorded
Phase 2/3	NCT01953510	Sep 2013 → Jan 2016	—	Murdoch Childrens Research Institute	Completed	No outcome recorded
Phase 2/3	NCT00611663	May 2008 → Dec 2014	systemic lupus erythematosus	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 362 trials
Phase 3	NCT06608199	Nov 2024 → Jun 2025 overdue	pneumococcal infection	Beijing Minhai Biotechnology Co., Ltd	Recruiting	No outcome recorded
Phase 3	NCT04214444	Jul 2020 → May 2024	diffuse large B-cell lymphoma, pneumococcal infection	University Hospital, Tours	Completed	No outcome recorded
Phase 3	NCT03547271	Dec 2018 → May 2023	meningococcal infection	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03620162	Oct 2018 → Dec 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03630705	Oct 2018 → Feb 2022	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03571607	Jul → Nov 2018	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03574389	Jun 2018 → Aug 2021	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03537508	Apr 2018 → Sep 2023	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03439657	Apr 2018 → May 2019	herpes zoster	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02943902	Jan 2017 → Feb 2019	meningitis, pneumonia	University of Witwatersrand, South Africa	Completed	No outcome recorded
Phase 3	NCT03205371	Nov 2016 → Jul 2018	meningococcal meningitis	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT02736240	Apr 2016 → Dec 2017	pneumococcal infection	Walvax Biotechnology Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02628886	Mar 2016 → Feb 2019	pneumonia	London School of Hygiene and Tropical Medicine	Unknown	No outcome recorded
Phase 3	NCT02225587	Aug 2014 → Jul 2015	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02094833	Mar 2014 → Apr 2016	diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01939158	Oct 2013 → Dec 2019	meningococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT01942174	Sep 2013 → Aug 2018	rheumatoid arthritis	University Hospital, Montpellier	Completed	No outcome recorded
Phase 3	NCT01892618	Aug 2013 → Dec 2015	chronic lymphocytic leukemia/small lymphocytic lymphoma	Karolinska University Hospital	Completed	No outcome recorded
Phase 3	NCT01641133	Sep 2012 → Jul 2013	pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01692886	Sep 2012 → Apr 2014	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT01646398	Jun → Oct 2012	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT01443416	Apr 2012 → Aug 2013	pneumococcal infection	University of Oxford	Completed	No outcome recorded
Phase 3	NCT01432158	Jan → Aug 2012	pneumococcal infection	University of Oxford	Completed	No outcome recorded
Phase 3	NCT02123433	Dec 2011 → Oct 2013	HIV infectious disease, pneumococcal infection	University of Siena	Completed	No outcome recorded
Phase 3	NCT01619462	Nov 2011 → Apr 2014	bacterial infectious disease, infectious disease with sepsis, meningitis, otitis media +1	Papua New Guinea Institute of Medical Research	Unknown	No outcome recorded
Phase 3	NCT01444781	Sep 2011 → Apr 2013	diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01432262	Jul → Dec 2011	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT01340937	May 2011 → Dec 2012	bacterial infectious disease, viral infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01177722	Aug 2010 → Oct 2011	diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01026038	Apr → Nov 2010	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00962780	Mar 2010 → Apr 2013	HIV infectious disease, pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00980655	Jan 2010 → May 2013	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00918580	Nov 2009 → Mar 2013	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00963235	Nov 2009 → May 2012	HIV infectious disease, pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00853749	May → Dec 2009	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00824655	Mar 2009 → Jun 2010	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00743652	Jan 2009 → Sep 2010	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00761631	Dec 2008 → Jul 2010	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00708682	Jul 2008 → May 2010	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00500266	May 2008 → Apr 2009	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00654901	Mar 2008 → May 2009	diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00999739	Dec 2007 → Apr 2008	HIV infectious disease	Hospital Universitari Son Dureta	Unknown	No outcome recorded
Phase 3	NCT00546572	Nov 2007 → Jul 2010	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00500357	Nov 2007 → Jan 2010	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00574548	Nov 2007 → Feb 2010	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00562354	Oct → Dec 2007	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00492557	Sep 2007 → Feb 2008	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00574795	Sep 2007 → Aug 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00521586	Sep 2007 → Dec 2013	influenza	Pfizer	Completed	No outcome recorded
Phase 3	NCT00452452	Jul 2007 → Mar 2008	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00464945	Jun 2007 → Sep 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00474526	Mar 2007 → Sep 2008	meningococcal meningitis	Novartis Vaccines	Completed	No outcome recorded
Phase 3	NCT00427895	Feb 2007 → Aug 2011	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00333450	Aug → Dec 2006	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00656409	Jun 2006 → Mar 2008	ataxia telangiectasia	Institute of Child Health	Completed	No outcome recorded
Phase 3	NCT00109343	Mar 2006 → Sep 2007	measles, mumps infectious disease, rubella, varicella zoster infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00189020	Jun 2005 → Feb 2008	pneumococcal infection	UMC Utrecht	Completed	No outcome recorded
Phase 3	NCT00772928	Oct 2003 → May 2006	diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1	Sanofi	Completed	No outcome recorded
Phase 3	NCT00197002	Sep 2003 → Jan 2006	hepatitis A virus infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00169728	Sep 2003 → Jun 2006	disease related to hematopoietic stem cell transplant	Heinrich-Heine University, Duesseldorf	Completed	No outcome recorded
Phase 3	NCT00622843	Dec 2002 → Jul 2013	HIV infectious disease, pneumococcal infection	Henry M. Jackson Foundation for the Advancement of Military Medicine	Completed	No outcome recorded
Phase 3	NCT00213265	Jul 2002 → Feb 2017	disease related to solid organ transplantation	The Hospital for Sick Children	Completed	No outcome recorded

Phase 442 trials
Phase 4	NCT07242092	Jun 2026 → Dec 2027 expected	rheumatic disorder	University of Sao Paulo General Hospital	Recruiting	No outcome recorded
Phase 4	NCT05329259	Oct → Nov 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 4	NCT05170399	Sep 2022 → Aug 2026 overdue	lymphoma	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	No outcome recorded
Phase 4	NCT04460235	Sep 2021 → Jun 2028 expected	non-Hodgkin lymphoma, pneumococcal infection	Poitiers University Hospital	Recruiting	No outcome recorded
Phase 4	NCT04875819	Apr 2021 → Dec 2026 expected	HIV infectious disease, meningococcal infection, pneumococcal infection	Thomas Benfield	Recruiting	No outcome recorded
Phase 4	NCT06210737	Sep 2019 → Nov 2022	pneumonia	Beijing Minhai Biotechnology Co., Ltd	Completed	No outcome recorded
Phase 4	NCT03489018	Mar 2019 → Sep 2022	pneumococcal infection	London School of Hygiene and Tropical Medicine	Completed	No outcome recorded
Phase 4	NCT05316831	Jan 2019 → Jun 2021	chronic lymphocytic leukemia/small lymphocytic lymphoma	Region Örebro County	Completed	No outcome recorded
Phase 4	NCT03777865	Dec 2018 → Apr 2019	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT03530124	Jul 2018 → Nov 2021	infantile apnea	Duke University	Completed	No outcome recorded
Phase 4	NCT03619252	Jul 2018 → Jan 2021	bacterial pneumonia, neutropenia, plasma cell myeloma, pneumococcal infection	Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology	Completed	No outcome recorded
Phase 4	NCT02637583	Oct 2017 → Nov 2022	pneumococcal infection	Jena University Hospital	Completed	No outcome recorded
Phase 4	NCT03260790	Oct 2017 → Dec 2020	asthma	Mayo Clinic	Completed	No outcome recorded
Phase 4	NCT07154537	Mar 2016 → Apr 2024 overdue	plasma cell myeloma	National Taiwan University Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT02422264	Jan 2016 → Mar 2018	diphtheria, poliomyelitis, tetanus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03041051	Dec 2015 → Mar 2017	HIV infectious disease	Aghia Sophia Children's Hospital of Athens	Unknown	No outcome recorded
Phase 4	NCT02124161	Sep 2014 → May 2015	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT02034877	Aug 2014 → Jul 2015	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT02072525	Apr 2014 → Jun 2015	meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02141009	Apr → Dec 2014	streptococcal pneumonia	St. Antonius Hospital	Completed	No outcome recorded
Phase 4	NCT01926860	Aug 2013 → Oct 2019	—	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT01939522	Aug 2013 → Apr 2016	type 1 diabetes mellitus	University of Oxford	Completed	No outcome recorded
Phase 4	NCT01974817	May → Dec 2013	end stage renal failure	Michigan State University	Completed	No outcome recorded
Phase 4	NCT01735084	Mar 2013 → Feb 2019	otitis media, respiratory tract infectious disorder	Menzies School of Health Research	Completed	No outcome recorded
Phase 4	NCT01577771	Feb 2013 → May 2014	pneumococcal infection	Agence de Médecine Préventive, France	Completed	No outcome recorded
Phase 4	NCT02492438	Feb 2013 → Feb 2014	chronic renal failure syndrome	AZ Sint-Jan AV	Completed	No outcome recorded
Phase 4	NCT01781871	Jan 2013 → Oct 2017	—	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT02787863	Sep 2012 → Dec 2016	asthma, chronic obstructive pulmonary disease, pneumococcal infection	Mikhael Petrovich Kostinov	Completed	No outcome recorded
Phase 4	NCT01597492	May 2012 → Sep 2015	systemic lupus erythematosus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01392378	Aug 2011 → Jan 2013	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT01846923	Oct 2010 → Feb 2012	beta-thalassemia major	Aghia Sophia Children's Hospital of Athens	Unknown	No outcome recorded
Phase 4	NCT01193582	Sep 2010 → Sep 2012	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 4	NCT01095471	Apr → Dec 2010	pneumococcal infection	University of Oxford	Completed	No outcome recorded
Phase 4	NCT00744263	Sep 2008 → Oct 2013	streptococcal pneumonia	Pfizer	Completed	No outcome recorded
Phase 4	NCT00828997	Aug 2008 → Jan 2018	rheumatoid arthritis, spondyloarthropathy	Region Skane	Completed	No outcome recorded
Phase 4	NCT00581035	Jan 2006 → May 2007	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00152802	Jan 2005 → Jan 2009	disease related to solid organ transplantation	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT00276107	Dec 2004 → Dec 2005	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00371878	Feb → Oct 2003	HIV infectious disease, meningitis, pneumococcal infection, pneumonia	Royal Liverpool University Hospital	Completed	No outcome recorded
Phase 4	NCT00304382	Jan 2003 → Sep 2006	pneumococcal infection, pneumonia	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT00143780	May 2002 → Jul 2006	bone marrow disorder	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT00239694	Apr 2001 → Aug 2012	—	National Institute on Aging (NIA)	Completed	No outcome recorded

Phase not applicable11 trials
—	NCT07591181	May 2026 → Dec 2027 expected	pneumococcal infection	Beijing Center for Disease Control and Prevention	Not yet recruiting	No outcome recorded
—	NCT06202703	Apr 2023 → Oct 2024	—	Leiden University Medical Center	Unknown	No outcome recorded
—	NCT02012309	Aug 2014 → Jun 2021	HIV infectious disease, pneumococcal infection	University of Colorado, Denver	Unknown	No outcome recorded
—	NCT01307449	Apr 2014 → Jul 2017	pneumococcal infection	Emory University	Completed	No outcome recorded
—	NCT01852591	Feb 2013 → Feb 2015	plasma cell myeloma	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
—	NCT02133469	Jun 2012 → Apr 2014	nasopharyngeal disorder, streptococcal pneumonia	Centers for Disease Control and Prevention, China	Completed	No outcome recorded
—	NCT01527591	Feb 2012 → Dec 2023 overdue	disease related to solid organ transplantation	University of California, Los Angeles	Active not recruiting	No outcome recorded
—	NCT01135082	Apr → Dec 2010	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
—	NCT00843895	Mar → Aug 2009	pneumococcal infection	King Saud University	Unknown	No outcome recorded
—	NCT00569309	Dec 2007 → Jul 2011	plasma cell myeloma, small intestine cancer	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
—	NCT00257127	Feb → Aug 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Also used as a comparator or background therapy in 202 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT03729778 Comparator	Jan 2017 → Mar 2020 overdue	AIDS	VA Eastern Colorado Health Care System	Active not recruiting	No outcome recorded
Phase 0	NCT02851056 Background	Sep 2016 → Jul 2018	plasma cell myeloma	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
Phase 0	NCT02558751 Comparator	Jul 2013 → Jun 2015	pneumococcal infection	University of Toledo Health Science Campus	Completed	No outcome recorded
Phase 119 trials
Phase 1	NCT07023081 Comparator	Jun 2025 → May 2027 expected	pneumococcal infection	Pfizer	Active not recruiting	No outcome recorded
Phase 1	NCT06970756 Comparator	May → Nov 2025 overdue	pneumococcal infection	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Not yet recruiting	No outcome recorded
Phase 1	NCT06800261 Comparator	May 2025 → Jun 2026 overdue	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Recruiting	No outcome recorded
Phase 1	NCT06550830 Comparator	Sep 2024 → Jun 2025	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT06562790 Comparator	Aug 2024 → Mar 2025	streptococcal pneumonia	GPN Vaccines	Completed	No outcome recorded
Phase 1	NCT06183216 Comparator	Jan 2024 → Mar 2025	pneumococcal infection	Sinovac Research and Development Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05667740 Comparator	Jan → Oct 2023	pneumococcal infection	GPN Vaccines	Completed	No outcome recorded
Phase 1	NCT05602480 Comparator	Nov 2022 → Jun 2024	pneumococcal infection	Wuhan BravoVax Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT04525599 Comparator	Sep 2020 → Apr 2022	pneumococcal infection	Affinivax, Inc.	Completed	No outcome recorded
Phase 1	NCT04830358 Comparator	May → Aug 2020	pneumococcal infection	EuBiologics Co.,Ltd	Completed	No outcome recorded
Phase 1	NCT04100772 Comparator	May 2020 → Jun 2021	pneumococcal infection	CanSino Biologics Inc.	Completed	No outcome recorded
Phase 1	NCT03848065 Comparator	Apr 2019 → Jun 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT06698198 Comparator	Dec 2018 → Sep 2019	idiopathic severe pneumococcemia	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 1	NCT03642847 Comparator	Aug 2018 → Mar 2019	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 1	NCT03549208 Comparator	Jul 2018 → Apr 2019	pneumococcal infection	LG Chem	Unknown	No outcome recorded
Phase 1	NCT03109600 Comparator	Apr → Sep 2017	—	PT Bio Farma	Completed	No outcome recorded
Phase 1	NCT02716805 Background	Dec 2016 → Feb 2018	plasma cell myeloma	Ludwig Institute for Cancer Research	Terminated	No outcome recorded
Phase 1	NCT01215175 Comparator	Sep 2009 → Apr 2010	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00834665 Background	Dec 2006 → Dec 2017	plasma cell myeloma	University of Pennsylvania	Completed	No outcome recorded

Phase 1/211 trials
Phase 1/2	NCT07600983 Comparator	May → Nov 2026 expected	pneumococcal infection	CanSino Biologics Inc.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT06647407 Background	Nov 2024 → May 2027 expected	meningococcal infection	Sanofi Pasteur, a Sanofi Company	Active not recruiting	No outcome recorded
Phase 1/2	NCT05982314 Comparator	Jul 2023 → Aug 2024	pneumococcal infection	GPN Vaccines	Completed	No outcome recorded
Phase 1/2	NCT03803202 Comparator	Jan 2019 → Sep 2020	bacterial pneumonia, pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 1/2	NCT03035331 Background	Aug 2017 → Jan 2022	T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +2	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT02531373 Comparator	Sep 2015 → Apr 2017	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1/2	NCT02308540 Comparator	Jan 2015 → Apr 2016	pneumococcal infection	PATH	Completed	No outcome recorded
Phase 1/2	NCT02037984 Comparator	Jan 2014 → Jul 2016	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1/2	NCT01312389 Background	Apr 2011 → May 2012	fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma	Abramson Cancer Center at Penn Medicine	Terminated	No outcome recorded
Phase 1/2	NCT00562939 Comparator	Jan 2008 → Jan 2009	HIV infectious disease	University of Aarhus	Completed	No outcome recorded
Phase 1/2	NCT00205803 Comparator	Sep 2004 → May 2007	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded

Phase 241 trials
Phase 2	NCT07300644 Comparator	Nov 2025 → Sep 2026 expected	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Recruiting	No outcome recorded
Phase 2	NCT05084508 Background	Feb 2022 → Feb 2024	chickenpox	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT04583618 Comparator	Oct 2020 → Aug 2021	—	Sanofi	Completed	No outcome recorded
Phase 2	NCT04515147 Comparator	Sep 2020 → Feb 2022	COVID-19, severe acute respiratory syndrome	CureVac	Completed	No outcome recorded
Phase 2	NCT04398706 Comparator	May 2020 → Aug 2023	chickenpox, diphtheria, haemophilus meningitis, hepatitis B virus infection +6	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 2	NCT03467984 Comparator	May → Oct 2018	pneumococcal infection	LG Chem	Completed	No outcome recorded
Phase 2	NCT03512288 Comparator	Apr 2018 → Feb 2020	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 2	NCT03313037 Comparator	Oct 2017 → Dec 2018	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 2	NCT02987972 Comparator	Mar 2017 → Oct 2018	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02573181 Comparator	Oct 2015 → Jan 2016	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02547649 Comparator	Oct 2015 → Jan 2016	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT02279589 Comparator	Dec 2014 → Jun 2016	pneumococcal infection	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01847781 Comparator	May → Nov 2013	selective IgG immunodeficiency	Karolinska University Hospital	Completed	No outcome recorded
Phase 2	NCT01616459 Comparator	Jul 2012 → Apr 2013	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01545375 Background	May 2012 → Jul 2016	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01513551 Comparator	Mar 2012 → Feb 2013	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT01349569 Background	Jan 2012 → Oct 2016	plasma cell myeloma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT01453998 Background	Oct 2011 → Nov 2012	diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01437267 Comparator	Oct 2011 → Aug 2012	typhoid fever	Novartis	Completed	No outcome recorded
Phase 2	NCT01245673 Background	May 2011 → Dec 2015	plasma cell myeloma	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT01282216 Comparator	Apr 2011 → Jan 2016	cancer-related condition	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded
Phase 2	NCT01229176 Comparator	Mar 2011 → Jun 2012	typhoid fever	Novartis	Completed	No outcome recorded
Phase 2	NCT01262872 Comparator	Feb 2011 → Mar 2013	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01248884 Background	Dec 2010 → Jan 2012	diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01215188 Comparator	Oct 2010 → Jul 2012	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT01204658 Comparator	Sep 2010 → Nov 2011	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01098474 Background	Jul 2010 → Apr 2011	tuberculosis	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01090453 Background	May 2010 → Oct 2011	diphtheria, haemophilus infectious disease, hepatitis B virus infection, meningococcal infection +2	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01414504 Comparator	Dec 2009 → Sep 2011	—	William Pomat	Completed	No outcome recorded
Phase 2	NCT01003418 Background	Nov 2009 → Nov 2010	influenza	GlaxoSmithKline	Terminated	No outcome recorded
Phase 2	NCT00871338 Background	Jun 2009 → Mar 2010	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00861744 Background	Jun 2009 → Jul 2010	measles, mumps infectious disease, rubella	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00689351 Comparator	Jun 2008 → Dec 2009	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 2	NCT00679159 Comparator	Feb 2008 → Dec 2009	tuberculosis	University of Oxford	Completed	No outcome recorded
Phase 2	NCT00578175 Background	Nov 2007 → Feb 2009	chickenpox, measles, mumps infectious disease, rubella	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00134719 Background	Apr 2005 → Jul 2006	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00323622 Comparator	Apr 2005 → May 2007	malaria	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00262002 Background	Sep 2004 → Jul 2005	meningococcemia	Novartis Vaccines	Completed	No outcome recorded
Phase 2	NCT00129129 Background	Aug 2004 → Sep 2005	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00127855 Background	Mar 2003 → Feb 2004	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00729001 Background	Nov 2000 → Sep 2002	Rotavirus infection	GlaxoSmithKline	Completed	No outcome recorded

Phase 395 trials
Phase 3	NCT07593924 Comparator	May 2026 → Jul 2027 expected	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 3	NCT07017777 Comparator	Nov 2025 → Feb 2027 expected	pneumococcal infection	CanSino Biologics Inc.	Recruiting	No outcome recorded
Phase 3	NCT06617715 Comparator	Oct 2024 → May 2026 overdue	pneumococcal infection	Sinovac Life Sciences Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT05934890 Comparator	Nov 2023 → Mar 2025 overdue	pneumococcal infection	Walvax Biotechnology Co., Ltd.	Active not recruiting	No outcome recorded
Phase 3	NCT05794230 Background	Mar 2023 → Nov 2025	meningococcal infection	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT05759520 Comparator	Nov 2022 → Jun 2025 overdue	pneumococcal infection	Fosun Adgenvax Biopharmaceutical Co.,Ltd.	Active not recruiting	No outcome recorded
Phase 3	NCT05512819 Comparator	Sep 2022 → Sep 2025	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT05408429 Comparator	Jun 2022 → Jun 2023	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04875533 Comparator	Jun 2021 → May 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04841369 Comparator	Apr 2021 → Mar 2022	pneumococcal infection	CanSino Biologics Inc.	Completed	No outcome recorded
Phase 3	NCT04530838 Comparator	Sep 2020 → Apr 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04546425 Comparator	Sep 2020 → Apr 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04384107 Comparator	Jul 2020 → Dec 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT04357522 Comparator	Jul 2020 → Mar 2026	streptococcal pneumonia	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Unknown	No outcome recorded
Phase 3	NCT04379713 Comparator	May 2020 → Aug 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT04382326 Comparator	May 2020 → Sep 2022	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03921424 Comparator	Nov 2019 → May 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT04031846 Comparator	Sep 2019 → Aug 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT04016714 Comparator	Aug 2019 → Oct 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03896477 Comparator	Jul 2019 → Dec 2020	streptococcal pneumonia	PATH	Completed	No outcome recorded
Phase 3	NCT03885934 Comparator	Jun 2019 → Dec 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03893448 Comparator	Jun 2019 → May 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03950622 Comparator	Jun 2019 → Mar 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03950856 Comparator	Jun 2019 → Apr 2020	streptococcal pneumonia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03828617 Comparator	Feb → Oct 2019	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03835975 Comparator	Feb 2019 → Feb 2020	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03731182 Comparator	Jan 2019 → Jun 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03692871 Comparator	Dec 2018 → Mar 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03760146 Comparator	Dec 2018 → Dec 2019	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT03632720 Background	Oct 2018 → Dec 2022	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03691610 Background	Oct 2018 → Oct 2023	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03673462 Background	Sep 2018 → Mar 2023	—	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT03565900 Comparator	Sep 2018 → Nov 2021	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03621670 Background	Jul 2018 → Dec 2024	meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT03547167 Comparator	Jul 2018 → Jan 2020	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03480802 Comparator	Jul 2018 → Sep 2019	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03480763 Comparator	Jun 2018 → Dec 2019	pneumococcal infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT03207750 Background	Sep 2017 → Oct 2018	Rotavirus infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02494999 Comparator	Jun 2016 → Dec 2018	pneumonia	Jiangsu Province Centers for Disease Control and Prevention	Completed	No outcome recorded
Phase 3	NCT02927444 Comparator	Nov 2015 → Oct 2017	pneumococcal infection	SK Chemicals Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02640703 Comparator	Mar 2015 → Dec 2016	—	University Hospital Tuebingen	Completed	No outcome recorded
Phase 3	NCT02173704 Comparator	Sep 2014 → Dec 2015	meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02201030 Comparator	Sep 2014 → Oct 2016	pneumococcal infection	SK Chemicals Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02096263 Background	Apr 2014 → Feb 2015	diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01978093 Background	Feb 2014 → Mar 2016	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01964716 Comparator	Jan → Sep 2014	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT01983540 Background	Oct 2013 → Jun 2015	diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01839188 Background	May 2013 → Mar 2014	meningococcal infection, viral infectious disease	MCM Vaccines B.V.	Completed	No outcome recorded
Phase 3	NCT01839175 Background	Apr 2013 → Jul 2014	meningococcal infection, viral infectious disease	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01702428 Background	Nov 2012 → Nov 2014	measles, mumps infectious disease, rubella	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01681992 Background	Oct 2012 → Feb 2015	measles, mumps infectious disease, rubella	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01553279 Background	Mar 2012 → Sep 2013	meningococcal infection, viral infectious disease	MCM Vaccines B.V.	Completed	No outcome recorded
Phase 3	NCT01480258 Background	Nov 2011 → Oct 2013	bacterial infectious disease, viral infectious disease	MCM Vaccines B.V.	Completed	No outcome recorded
Phase 3	NCT01439360 Comparator	Oct 2011 → Oct 2014	influenza	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01411241 Background	Jul 2011 → Feb 2014	Dengue hemorrhagic fever	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT01341639 Background	May 2011 → Mar 2013	bacterial infectious disease, viral infectious disease	MCM Vaccines B.V.	Completed	No outcome recorded
Phase 3	NCT01337167 Background	Apr 2011 → May 2013	bacterial infectious disease, viral infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01214837 Background	Oct 2010 → Apr 2012	meningococcal meningitis	Novartis Vaccines	Completed	No outcome recorded
Phase 3	NCT01200368 Comparator	Sep 2010 → Nov 2011	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT01218451 Background	Sep 2010 → Jan 2012	meningococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT01000974 Background	Jun 2010 → Nov 2011	haemophilus infectious disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01041573 Comparator	Mar 2010 → Feb 2011	encephalitis	Valneva Austria GmbH	Completed	No outcome recorded
Phase 3	NCT00907777 Comparator	Jun → Oct 2009	pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00911144 Comparator	Jun 2009 → Jan 2010	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00680914 Comparator	Jun 2008 → May 2009	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00688870 Comparator	Jun 2008 → Jan 2010	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00652951 Comparator	Apr 2008 → May 2009	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00676091 Comparator	Apr 2008 → Sep 2009	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00624819 Background	Mar → Jun 2008	pneumococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00617760 Comparator	Mar 2008 → Aug 2009	meningococcal meningitis, pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00667602 Background	Mar 2008 → Jul 2009	meningococcal meningitis	Novartis Vaccines	Completed	No outcome recorded
Phase 3	NCT00657709 Comparator	Mar 2008 → Jan 2010	meningococcal meningitis	Novartis Vaccines	Completed	No outcome recorded
Phase 3	NCT00586612 Background	Dec 2007 → Dec 2008	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00508742 Comparator	Dec 2007 → Aug 2011	pneumococcal infection	Pfizer	Completed	No outcome recorded
Phase 3	NCT00594347 Comparator	Nov 2007 → Mar 2008	pneumococcal infection	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00547248 Comparator	Oct 2007 → May 2008	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00474539 Comparator	Jul 2007 → Mar 2009	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00345683 Background	Jul 2007 → Sep 2008	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00452790 Comparator	Jun 2007 → Oct 2009	pneumococcal infection	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00475033 Comparator	Jun 2007 → May 2009	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00444457 Comparator	May 2007 → Jun 2009	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00463437 Comparator	Apr 2007 → Jan 2008	diphtheria, hepatitis B virus infection, pneumococcal infection, poliomyelitis +1	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00457977 Comparator	Mar 2007 → May 2011	chronic obstructive pulmonary disease	University of Minnesota	Completed	No outcome recorded
Phase 3	NCT00366548 Comparator	Nov 2006 → Jun 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00368966 Comparator	Oct 2006 → Jul 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00401531 Background	Oct 2006 → Nov 2007	diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00366340 Comparator	Oct 2006 → Aug 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00384059 Comparator	Oct 2006 → Oct 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00366678 Comparator	Oct 2006 → Nov 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00366899 Comparator	Oct 2006 → Jul 2008	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00370396 Comparator	Sep 2006 → Jun 2007	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00373958 Comparator	Sep 2006 → Jun 2008	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00344318 Comparator	Aug 2006 → Apr 2007	streptococcal infection	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00343421 Background	Jul 2006 → Jun 2008	diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1	Sanofi Pasteur, a Sanofi Company	Completed	No outcome recorded
Phase 3	NCT00289783 Background	Feb 2006 → Aug 2007	haemophilus infectious disease, meningococcal infection	GlaxoSmithKline	Completed	No outcome recorded

Phase 429 trials
Phase 4	NCT04978038 Comparator	Aug → Nov 2022	COVID-19	Mark Loeb	Unknown	No outcome recorded
Phase 4	NCT04974294 Comparator	Jul 2021 → Jul 2023	streptococcal pneumonia	Liverpool School of Tropical Medicine	Unknown	No outcome recorded
Phase 4	NCT04535037 Background	May 2021 → Jul 2022	diphtheria	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT04080531 Background	Oct 2019 → May 2021	plasma cell neoplasm	Emory University	Completed	No outcome recorded
Phase 4	NCT03565159 Comparator	Aug 2018 → Aug 2023	infectious disease with sepsis	Guy's and St Thomas' NHS Foundation Trust	Completed	No outcome recorded
Phase 4	NCT03548337 Comparator	May 2018 → Dec 2019	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT03165981 Background	Aug 2017 → Jan 2018	—	Duke University	Completed	No outcome recorded
Phase 4	NCT03104075 Comparator	Apr 2017 → Dec 2019	pneumonia	The Jackson Laboratory	Completed	No outcome recorded
Phase 4	NCT03762824 Comparator	Jun 2016 → Sep 2018	Sjogren syndrome, rheumatoid arthritis, spondyloarthropathy, systemic lupus erythematosus +1	Region Skane	Completed	No outcome recorded
Phase 4	NCT02447718 Comparator	Nov 2015 → Mar 2018	acute lymphoblastic leukemia	Canadian Immunization Research Network	Completed	No outcome recorded
Phase 4	NCT02370069 Comparator	Jun 2015 → Aug 2020	chronic kidney disease	Lakehead University	Completed	No outcome recorded
Phase 4	NCT03838497 Comparator	Apr 2015 → Jan 2017	HIV infectious disease, streptococcal pneumonia	Korea University Guro Hospital	Completed	No outcome recorded
Phase 4	NCT02215863 Comparator	Sep 2014 → Mar 2015	influenza, pneumococcal infection	Korea University Guro Hospital	Completed	No outcome recorded
Phase 4	NCT02002156 Background	Jun 2014 → Aug 2016	tuberculosis	University of Oxford	Completed	No outcome recorded
Phase 4	NCT03552445 Comparator	Nov 2013 → Apr 2016	diphtheria, pneumococcal infection, tetanus	Korea University Guro Hospital	Completed	No outcome recorded
Phase 4	NCT03095326 Background	Sep 2013 → Feb 2014	pneumococcal infection, thalassemia	Faculty of Medicine, University of Indonesia	Completed	No outcome recorded
Phase 4	NCT01947010 Comparator	Jul 2013 → Aug 2014	Crohn disease	Statens Serum Institut	Completed	No outcome recorded
Phase 4	NCT02582047 Comparator	Oct → Dec 2012	influenza, pneumococcal infection	Korea University Guro Hospital	Completed	No outcome recorded
Phase 4	NCT01174849 Comparator	Aug 2011 → Sep 2017	otitis media	Menzies School of Health Research	Completed	No outcome recorded
Phase 4	NCT01193335 Comparator	Oct 2010 → Jan 2014	—	Pfizer	Completed	No outcome recorded
Phase 4	NCT01346007 Comparator	Jan 2009 → Jun 2010	idiopathic nephrotic syndrome	National and Kapodistrian University of Athens	Unknown	No outcome recorded
Phase 4	NCT00836641 Comparator	Oct 2006 → Oct 2008	asthma	Johann Wolfgang Goethe University Hospital	Completed	No outcome recorded
Phase 4	NCT00390130 Comparator	Jul 2006 → Jun 2007	—	The Hospital for Sick Children	Completed	No outcome recorded
Phase 4	NCT00312858 Comparator	Apr 2006 → Mar 2008	hepatitis A virus infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00294294 Background	May 2005 → Dec 2006	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT01402245 Comparator	Jan 2005 → Jun 2010	streptococcal pneumonia	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT00581620 Comparator	Nov 2002 → Sep 2007	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00023504 Comparator	Jun 2002 → May 2017	immunodeficiency disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 4	NCT02918708 Comparator	? → Jan 2017	—	Public Health England	Withdrawn	No outcome recorded

Phase not applicable4 trials
—	NCT05939219 Comparator	Jul 2023 → Jan 2025	—	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Unknown	No outcome recorded
—	NCT02547493 Comparator	Mar 2016 → Jan 2021	rheumatoid arthritis	University Hospital, Montpellier	Completed	No outcome recorded
—	NCT02240888 Comparator	Oct 2011 → Dec 2017	Sjogren syndrome, rheumatoid arthritis, scleroderma, systemic lupus erythematosus +1	Region Skane	Completed	No outcome recorded
—	NCT01263210 Comparator	Mar 2003 → Jun 2009	otitis media	Lund University Hospital	Completed	No outcome recorded

Press releases naming this drug 32 releases

Date	Issuer	Release
2026-05-20	Pfizer	Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results pfizer.com ↗
2024-10-23	Pfizer	Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older pfizer.com ↗
2024-03-13	Pfizer	European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease pfizer.com ↗
2023-04-27	Pfizer	U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children pfizer.com ↗
2023-01-06	Pfizer	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children pfizer.com ↗
2022-09-19	Pfizer	Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union pfizer.com ↗
2022-08-12	Pfizer	Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants pfizer.com ↗
2022-02-15	Pfizer	European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults pfizer.com ↗
2022-01-12	Pfizer	Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released pfizer.com ↗
2021-12-17	Pfizer	CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults pfizer.com ↗
2021-10-20	Pfizer	Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults pfizer.com ↗
2021-09-29	Pfizer	Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released pfizer.com ↗
2021-06-08	Pfizer	U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older pfizer.com ↗
2021-05-24	Pfizer	Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults pfizer.com ↗
2021-02-26	Pfizer	European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older pfizer.com ↗
2020-12-08	Pfizer	U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older pfizer.com ↗
2020-10-21	Pfizer	Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020 pfizer.com ↗
2020-05-14	Pfizer	Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age pfizer.com ↗
2020-03-18	Pfizer	Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older pfizer.com ↗
2019-09-09	Pfizer	Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants pfizer.com ↗
2019-04-13	Pfizer	Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗
2019-02-28	Pfizer	Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗
2018-12-14	Pfizer	Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗
2018-09-20	Pfizer	Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older pfizer.com ↗
2018-05-22	Pfizer	A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+ pfizer.com ↗
2016-11-02	Pfizer	Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China pfizer.com ↗
2016-07-19	Pfizer	Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13® pfizer.com ↗
2016-07-12	Pfizer	Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49 pfizer.com ↗
2016-04-06	Pfizer	Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13® pfizer.com ↗
2015-03-03	Pfizer	Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults pfizer.com ↗
2015-01-26	Pfizer	Pfizer Commits to Further Reduce Price for Prevenar 13 in the World’s Poorest Countries Through 2025 pfizer.com ↗
2015-01-22	Pfizer	Prevenar 13®* Receives CHMP Positive Opinion For Prevention Of Vaccine-Type Pneumococcal Pneumonia in Adults pfizer.com ↗

Evidence & citations 49 cited values

Every value below carries the sentence it was read from. 427 sources stand behind the page.

Field	Value	Cited text
Known as	Prevnar-13	“Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,...” NCT03619252 ↗ 75 “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ “13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine.” NCT02851056 ↗ “Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.” NCT03104075 ↗ “13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.])” PMID 21150868 ↗ Dec 2010 “vaccine with pneumococcal polysaccharides of 13 different serotypes conjugated to a protein (Prevnar13)” NCT06202703 ↗ “A new vaccine, Prevnar13, has superior immunogenicity and has been recently approved for immunization.” NCT02370069 ↗ “Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) at 2, 3 and 4 months of age” PMID 27846055 ↗ Feb 2017 “PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age” NCT03673462 ↗ “Concomitant Prevnar 13 was given to all groups at 2, 4, 6 and 15 months” PMID 27846058 ↗ Feb 2017 “received a 3-dose primary vaccination course of Prevnar13™ vaccine” NCT01616459 ↗ “Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine.” NCT01654263 ↗ “Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)” NCT03950622 ↗ “a 13-valent pneumococcal conjugate vaccine (Prevnar 13)” NCT05084508 ↗ “or Prevnar13 in Healthy Adults” NCT02892812 ↗ “Prevnar 13 #1” NCT00505063 ↗ NCT02531373 ↗ NCT01337167 ↗ NCT02225587 ↗ NCT04978038 ↗ NCT03549208 ↗ NCT01513551 ↗ NCT06698198 ↗ NCT03376477 ↗ NCT03547167 ↗ NCT07017777 ↗ NCT01732198 ↗ NCT03950856 ↗ NCT02096263 ↗ NCT01681992 ↗ NCT01978093 ↗ NCT06183216 ↗ NCT02370069 ↗ NCT02447718 ↗ NCT03550313 ↗ NCT02987972 ↗ NCT02072525 ↗ NCT02494999 ↗ NCT03313037 ↗ NCT02716805 ↗ NCT02201030 ↗ NCT01553279 ↗ NCT01215188 ↗ NCT02141009 ↗ NCT02547649 ↗ NCT03731182 ↗ NCT02573181 ↗ NCT03565900 ↗ NCT03467984 ↗ NCT03642847 ↗ NCT02927444 ↗ NCT03729778 ↗ NCT03885934 ↗ NCT01262872 ↗ NCT02851056 ↗ NCT01349569 ↗ NCT03819049 ↗ NCT02037984 ↗ NCT02422264 ↗ NCT04583618 ↗ NCT05170399 ↗ NCT05412030 ↗ NCT03921424 ↗ NCT01616459 ↗ NCT03893448 ↗ NCT07333352 ↗ NCT01577771 ↗ NCT03692871 ↗ NCT03620162 ↗ NCT01545375 ↗ NCT01340937 ↗ NCT01000974 ↗ NCT03621670 ↗ NCT03480802 ↗ NCT03480763 ↗ NCT01702428 ↗
Known as	11PCV Vaccine	“An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.” NCT00327522 ↗
Known as	13 valent conjugated pneumococcal vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03039491 ↗ 1 NCT03802994 ↗
Known as	13-valent conjugate pneumococcal vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01974817 ↗
Known as	13-valent PCV	“A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13).” PMID 34525007 ↗ Oct 2021 2 “Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden.” PMID 34315611 ↗ Jul 2021 “A recently licensed 13-valent PCV (PCV13) was developed to provide additional coverage globally.” PMID 21983216 ↗ Dec 2011
Known as	13-valent Pneumoccocal Conjugate Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00918580 ↗
Known as	13-valent pneumococcal conjugate vaccine	“Subjects aged ⩾60years were randomized in a 1:1:1 ratio to receive MF59-adjuvanted trivalent inactivated influenza vaccine (MF59-aTIV)+13-valent pneumococcal conjugate vaccine...” PMID 27919632 ↗ Dec 2016 66 “A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the...” PMID 34839993 ↗ Nov 2021 “13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine.” NCT02851056 ↗ “BACKGROUND: 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China based on immunologic noninferiority to 7-valent PCV (PCV7).” PMID 31626050 ↗ Nov 2019 “the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia” PMID 29017280 ↗ Sep 2017 “The 13-valent pneumococcal conjugate vaccine (PCV13) has superior immunogenicity in some categories of immunocompromised adults” PMID 31718534 ↗ Nov 2019 “a 13-valent pneumococcal conjugate vaccine (PCV13) induces robust early immune responses in such patients” PMID 30683996 ↗ Jan 2019 “the 13-valent pneumococcal conjugate vaccine (PCV13) has sufficient immunogenicity in children” PMID 39217777 ↗ Aug 2024 “13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid” NCT02628886 ↗ “13-valent Pneumococcal Conjugate Vaccine (Prevenar13®)” NCT01781871 ↗ “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 29722823 ↗ Jun 2018 “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 34656378 ↗ Oct 2021 NCT00427895 ↗ NCT00963235 ↗ NCT00474539 ↗ NCT00761631 ↗ NCT01026038 ↗ NCT00384059 ↗ NCT00574548 ↗ NCT01531322 ↗ NCT03571607 ↗ NCT00708682 ↗ NCT02558751 ↗ NCT00475033 ↗ NCT00368966 ↗ NCT04357522 ↗ NCT05329259 ↗ NCT00444457 ↗ NCT06970756 ↗ NCT00508742 ↗ NCT00452790 ↗ NCT00269672 ↗ NCT04382326 ↗ NCT04546425 ↗ NCT02034877 ↗ NCT01200368 ↗ NCT00689351 ↗ NCT00676091 ↗ NCT00452452 ↗ NCT00464945 ↗ NCT01646398 ↗ NCT05512819 ↗ NCT00743652 ↗ NCT00824850 ↗ NCT04379713 ↗ NCT03762824 ↗ NCT00366899 ↗ NCT00205803 ↗ NCT00366678 ↗ NCT00366548 ↗ NCT00366340 ↗ NCT01392378 ↗ NCT01964716 ↗ NCT00500357 ↗ NCT02124161 ↗ NCT00492557 ↗ NCT00688870 ↗ NCT00500266 ↗ NCT06703203 ↗ NCT00546572 ↗ NCT00521586 ↗ NCT00853749 ↗ NCT01193335 ↗ NCT05408429 ↗ NCT04530838 ↗ NCT02482636 ↗ NCT05084508 ↗
Known as	13-Valent Pneumococcal Polysaccharide Conjugate Vaccine	“13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)” NCT07333352 ↗ 9 NCT05092386 ↗ NCT04841369 ↗ NCT06675032 ↗ NCT07591181 ↗ NCT05939219 ↗ NCT02736240 ↗ NCT05602480 ↗ NCT04100772 ↗ NCT07600983 ↗
Known as	13-valent Pnumococcal Conjugate vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01692886 ↗
Known as	13vPnC	“The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal...” NCT00366340 ↗ 34 “The objective of this study is to compare the immune response of 2 different 13-valent pneumococcal conjugate (13vPnC) formulations with and without AlPO4 to select a...” NCT00269672 ↗ “This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have...” NCT00500357 ↗ “The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal...” NCT00373958 ↗ “Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly...” NCT00492557 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00474539 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366899 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00368966 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366678 ↗ “Participants will receive either the study vaccine (20vPnC) or a licensed vaccine (13vPnC) as a 4-dose schedule as a shot in the muscle.” NCT05512819 ↗ “a 13-valent Pneumococcal conjugate vaccine (13vPnC)” NCT00452452 ↗ “13-valent Pneumococcal Conjugate Vaccine (13vPnC)” NCT00500266 ↗ “13-valent pneumococcal conjugate vaccine (13vPnC)” NCT00427895 ↗ “13-valent pneumococcal conjugate (13vPnC) vaccine” NCT00384059 ↗ “13-valent pneumococcal conjugate vaccine (13vPnC)” NCT00521586 ↗ “13-valent pneumococcal conjugate vaccine (13vPnC)” NCT00853749 ↗ “13-valent pneumococcal conjugate vaccine (13vPnC)” NCT00688870 ↗ “13-Valent Pneumococcal Conjugate Vaccine (13vPnC)” NCT00205803 ↗ “13-Valent Pneumococcal Conjugate Vaccine (13vPnC)” NCT00676091 ↗ “study vaccine (13vPnC)” NCT05329259 ↗ NCT05489328 ↗ NCT00962780 ↗ NCT07019909 ↗ NCT03548337 ↗ NCT00980655 ↗ NCT04875533 ↗ NCT00574795 ↗ NCT03574389 ↗ NCT03828617 ↗ NCT03777865 ↗ NCT07023081 ↗ NCT00824655 ↗ NCT03760146 ↗ NCT00562354 ↗ NCT03835975 ↗
Known as	20-valent Pneumococcal Conjugate Vaccine (PCV20)	“20-valent Pneumococcal Conjugate Vaccine (PCV20)” NCT07242092 ↗
Known as	7 - valent PCV	“In Thailand, 7 - valent PCV (Prevnar® ) was available in 2003.” NCT01135082 ↗
Known as	7 valent pneumococcal conjugate vaccine	“This study aimed to determine the immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV-7) in Thai HIV-infected children compared to HIV-exposed...” PMID 21729732 ↗ Jul 2011 22 “BACKGROUND: Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in Chinese infants.” PMID 27254028 ↗ Sep 2016 “A 7-valent pneumococcal conjugate vaccine (PCV-7) was licensed in 2000 (Prevnar™, Wyeth Lederle Vaccines)” NCT00153543 ↗ “7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar” NCT00900978 ↗ NCT00452790 ↗ NCT00474539 ↗ NCT00368966 ↗ NCT00488826 ↗ NCT00475033 ↗ NCT01200368 ↗ NCT00508742 ↗ NCT00689351 ↗ NCT00676091 ↗ NCT02736240 ↗ NCT01692886 ↗ NCT00366340 ↗ NCT00366899 ↗ NCT00366678 ↗ NCT00205803 ↗ NCT00148824 ↗ NCT00688870 ↗ NCT01346007 ↗ NCT00213265 ↗
Known as	7v-PCV	“7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar” NCT00900978 ↗
Known as	7vPnC	“The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal...” NCT00366340 ↗ 12 “The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal...” NCT00373958 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00474539 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366899 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00368966 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366678 ↗ “We performed an open-label, randomized study that compared 7-valent pneumococcal conjugate vaccine (7vPnC) with PPV in 599 adults aged 50-80 years.” PMID 19814624 ↗ Nov 2009 “7-Valent Pneumococcal Conjugate Vaccine (7vPnC)in healthy Chinese infants” NCT00488826 ↗ “7-Valent Pneumococcal Conjugate Vaccine (7vPnC)” NCT00205803 ↗ “7-valent pneumococcal conjugate vaccine (7vPnC)” NCT00688870 ↗ “7-Valent Pneumococcal Conjugate Vaccine (7vPnc)” NCT00676091 ↗ NCT00384059 ↗ NCT00444457 ↗
Known as	DTaP-IPV-Hep B-PRP-T Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01177722 ↗ 1 NCT00654901 ↗
Known as	DTaP-IPV-Hep B-PRP~T combined vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01444781 ↗ 1 NCT02094833 ↗
Known as	Multivalent	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955160 ↗
Known as	PCV	“a 7-valent conjugate pneumococcal vaccine (PCV)” PMID 18025879 ↗ Nov 2007
Known as	PCV-13	“This open-label randomized controlled trial in infants compared safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) formulated with...” PMID 28479175 ↗ May 2017 81 “A 13-valent pneumococcal conjugate vaccine (PCV13) containing 6 additional serotypes not included in the 7-valent PCV has been developed to broaden protection against...” PMID 23538524 ↗ Sep 2013 “This phase 3, randomized, partially double-blind study investigated the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine (PCV20) in healthy...” PMID 40081152 ↗ Mar 2025 “This open-label multicenter clinical trial conducted in Mexico assessed the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) in adults ≥ 50 years...” PMID 25499011 ↗ Dec 2014 “Subjects aged ⩾60years were randomized in a 1:1:1 ratio to receive MF59-adjuvanted trivalent inactivated influenza vaccine (MF59-aTIV)+13-valent pneumococcal conjugate vaccine...” PMID 27919632 ↗ Dec 2016 “13-valent pneumococcal conjugate vaccine (PCV13) includes polysaccharide conjugates from six pneumococcal serotypes in addition to those in the licensed 7-valent vaccine,...” PMID 21335032 ↗ Feb 2011 “The objective of this study was to provide safety data for single-dose 13-valent pneumococcal conjugate vaccine (PCV13) in Chinese subjects, needed to begin a phase III safety...” PMID 26668712 ↗ Dec 2015 “This study assessed whether paracetamol or ibuprofen prophylaxis interfere with immune responses to the 13-valent pneumococcal conjugate vaccine (PCV13) given concomitantly...” PMID 28262330 ↗ Mar 2017 “This phase 3, double-blind study randomized healthy Japanese infants to receive 4 doses (3 infant doses, 1 toddler dose) of PCV20 by subcutaneous (SC) or intramuscular (IM)...” PMID 38242195 ↗ Jan 2024 “The safety and immunogenicity of PCV7 were compared with those of 13-valent PCV (PCV13), which contains saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,...” PMID 20435707 ↗ May 2010 “Currently in the UK, 3 doses of a vaccine called Prevenar 13 (PCV-13), which contains 13 pneumococcal serotypes attached to a carrier protein called CRM197, are given to...” NCT01443416 ↗ “pneumococcal vaccination with either the 23-valent pneumococcal polysaccharide vaccine PPV-23 (Pneumovax-23) alone or the 13-valent pneumococcal conjugate vaccine PCV-13...” NCT03039491 ↗ “This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate...” PMID 24576885 ↗ Feb 2014 “Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®)...” PMID 21704105 ↗ Jun 2011 “The 13-valent pneumococcal conjugate vaccine (PCV13) is approved and World Health Organization-prequalified for administration in a 2+1 schedule when used as part of routine...” PMID 23965217 ↗ Aug 2013 “This open-label, single-arm, phase 3 study evaluated safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal vaccine-naive Japanese individuals” PMID 34563397 ↗ Sep 2021 “This study was performed to support licensure of a 13-valent pneumococcal conjugate vaccine (PCV13), which expands serotype coverage to include serotypes 1, 3, 5, 6A, 7F and 19A.” PMID 23584582 ↗ Aug 2013 “A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13).” PMID 34525007 ↗ Oct 2021 “The immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13 and PCV7) were compared when administered with routine vaccines in Korea.” PMID 23011012 ↗ Mar 2013 “This phase 3, randomized (1:1), double-blind study evaluated safety and immunogenicity of 20-valent PCV (PCV20) relative to 13-valent PCV (PCV13) in healthy infants.” PMID 38456705 ↗ Mar 2024 “They received an injection of 13-valent conjugate vaccine (PCV13), followed by an injection of 23-valent polysaccharide vaccine (PPV23) at least 2 months later.” NCT04460235 ↗ “13-Valent pneumococcal conjugate vaccine (PCV13) provides broader protection against pneumococcal disease than 7-valent pneumococcal conjugate vaccine (PCV7).” PMID 26121200 ↗ Oct 2015 “13-Valent pneumococcal conjugate vaccine (PCV13) (PCV7 serotypes plus 1, 3, 5, 6A, 7F, and 19A) was designed to provide broader pneumococcal disease coverage.” PMID 20732948 ↗ Aug 2010 “This study assessed the persistence of antibody response to the 13-valent pneumococcal conjugate vaccine (PCV13) in formerly preterm versus term infants.” PMID 27902652 ↗ Mar 2017 “Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden.” PMID 34315611 ↗ Jul 2021 “BACKGROUND: 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in China based on immunologic noninferiority to 7-valent PCV (PCV7).” PMID 31626050 ↗ Nov 2019 “three 13-valent pneumococcal conjugate vaccine (PCV13) doses followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23)” PMID 25888646 ↗ Jul 2015 “The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend pneumococcal disease protection beyond 13-valent PCV (PCV13).” PMID 38535409 ↗ Mar 2024 “13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.])” PMID 21150868 ↗ Dec 2010 “the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia” PMID 29017280 ↗ Sep 2017 “Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children.” PMID 22198517 ↗ Dec 2011 “A total of 103 children aged 5 to 17 years with SCD were randomized and received a single dose of V114 or Prevnar 13 (PCV13).” PMID 36383730 ↗ Feb 2023 “the investigators would like to study the use of an alternative vaccine against pneumococcus called Prevenar13 (or pCV13).” NCT01939522 ↗ “13-valent pneumococcal CRM197 conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F)” PMID 24300594 ↗ Dec 2013 “We evaluated the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in this population.” PMID 27581438 ↗ Nov 2016 “Both groups received concomitantly Prevnar 13 (PCV13) and Rotateq (RV5) at 2, 3 and 4 months of age” PMID 27846055 ↗ Feb 2017 “Participants were randomized to receive PCV20 or 13-valent pneumococcal conjugate vaccine (PCV13).” PMID 38267330 ↗ Jan 2024 “A recently licensed 13-valent PCV (PCV13) was developed to provide additional coverage globally.” PMID 21983216 ↗ Dec 2011 “PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age” NCT03673462 ↗ “Prevnar13 (PCV13) was administered intramuscularly on Day 1, Day 61, Day 121 and Day 301.” NCT03621670 ↗ “13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months” NCT02482636 ↗ “13-valent pneumococcal polysaccharide conjugate vaccine (referred to as PCV13)” NCT07600983 ↗ “V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ (PCV13)” PMID 36522265 ↗ Dec 2022 “investigational 13-valent pneumococcal conjugate vaccine (PCV13)” PMID 27798013 ↗ Oct 2016 “single dose 13-valent conjugate pneumococcal vaccine (PCV-13)” NCT03565159 ↗ “Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine.” NCT01654263 ↗ “initial 13-valent PCV (PCV13) or 23-valent PPSV (PPSV23)” PMID 24606865 ↗ Mar 2014 “a 0+1 schedule of PCV13 at 12 months of age (Group W)” NCT03098628 ↗ “Pneumococcal 13-valent conjugate vaccine (PCV-13)” NCT02049138 ↗ “13-valent (PCV-13) pneumococcal conjugate vaccine” PMID 24618837 ↗ Mar 2014 “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 27155493 ↗ May 2016 “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 34656378 ↗ Oct 2021 “Prevenar13 (PCV13) and Pneumovax (PPS23)” NCT03873727 ↗ “13-valent PCV (PCV13)” PMID 34940806 ↗ Aug 2022 NCT03384589 ↗ NCT03489018 ↗ NCT03041051 ↗ NCT02637583 ↗ NCT01852591 ↗ NCT02943902 ↗ NCT00566098 ↗ NCT04525599 ↗ NCT06210737 ↗ NCT01095471 ↗ NCT01953510 ↗ NCT04384107 ↗ NCT03803202 ↗ NCT01282216 ↗ NCT03205371 ↗ NCT05934890 ↗ NCT03530124 ↗ NCT04974294 ↗ NCT05316831 ↗ NCT01846923 ↗ NCT03165981 ↗ NCT03619252 ↗ NCT03552445 ↗ NCT03260790 ↗ NCT03069703 ↗ NCT07154537 ↗ NCT02492438 ↗ NCT02012309 ↗
Known as	PCV13 vaccine	“1 dose ( 0.5ml) of PCV13 vaccine” NCT07600983 ↗ 1 NCT01443117 ↗
Known as	PCV20	“All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0).” NCT07242092 ↗
Known as	PCV7	“This open-label, multicenter, randomized, comparative study evaluated immunogenicity, safety and tolerability of concomitant (Group 1; n=330) vs. non-concomitant (Group 2;...” PMID 23744509 ↗ Jun 2013 22 “The 7-valent pneumococcal conjugate vaccine (PCV7) has demonstrated effectiveness against pneumococcal illnesses when administered as 3 infant doses plus a toddler dose (3+1...” PMID 23965217 ↗ Aug 2013 “HIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5...” PMID 23954381 ↗ Aug 2013 “7-Valent pneumococcal conjugate vaccine (PCV7 [Prevnar, Wyeth Pharmaceuticals Inc, Philadelphia, PA], serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) is effective in preventing...” PMID 20732948 ↗ Aug 2010 “Invasive pneumococcal disease rates have declined since immunization with 7-valent pneumococcal conjugate vaccine (PCV7) (Prevenar/Prevnar [Wyeth Pharmaceuticals, Philadelphia,...” PMID 20435707 ↗ May 2010 “This study aimed to determine the immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV-7) in Thai HIV-infected children compared to HIV-exposed...” PMID 21729732 ↗ Jul 2011 “BACKGROUND: Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in Chinese infants.” PMID 27254028 ↗ Sep 2016 “The immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13 and PCV7) were compared when administered with routine vaccines in Korea.” PMID 23011012 ↗ Mar 2013 “13-Valent pneumococcal conjugate vaccine (PCV13) provides broader protection against pneumococcal disease than 7-valent pneumococcal conjugate vaccine (PCV7).” PMID 26121200 ↗ Oct 2015 “The 7-valent pneumococcal conjugate vaccine (PCV7; serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) has decreased invasive pneumococcal disease incidence.” PMID 23584582 ↗ Aug 2013 “Immunogenicity and safety of 13-valent and 7-valent pneumococcal conjugate vaccines (PCV13; PCV7) were compared in Taiwanese children.” PMID 22198517 ↗ Dec 2011 “heptavalent pneumococcal conjugate vaccine (Prevenar 7; PCV7) and non-vaccinated individually matched arthritis patients.” PMID 25656734 ↗ Feb 2015 “Seven-valent pneumococcal conjugate vaccine (PCV-7) is effective against vaccine serotype disease and carriage.” PMID 24447437 ↗ Feb 2014 “A 7-valent pneumococcal conjugate vaccine (PCV-7) was licensed in 2000 (Prevnar™, Wyeth Lederle Vaccines)” NCT00153543 ↗ “currently licensed 7-valent pneumococcal conjugate vaccine (PCV7)” PMID 27798013 ↗ Oct 2016 “heptavalent pneumococcal vaccine (PCV7; Prevnar(®), Pfizer)” PMID 25424793 ↗ 2014 “Prevenar (PCV7)” NCT01983540 ↗ NCT00617760 ↗ NCT00169234 ↗ NCT00189020 ↗ NCT02133469 ↗ NCT00153543 ↗ NCT00667602 ↗
Known as	Pneumoccocal Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794230 ↗
Known as	Pneumococcal 13-valent Conjugate Vaccine	“Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae...” NCT01214837 ↗ 14 NCT03673462 ↗ NCT04398706 ↗ NCT01654263 ↗ NCT02049138 ↗ NCT04080531 ↗ NCT02309515 ↗ NCT03630705 ↗ NCT03035331 ↗ NCT03537508 ↗ NCT04535037 ↗ NCT02518555 ↗ NCT03942328 ↗ NCT06647407 ↗ NCT03691610 ↗
Known as	Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01049035 ↗
Known as	Pneumococcal 13-valent Conjugate Vaccine (PCV13)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03848065 ↗
Known as	Pneumococcal 13-valent polysaccharide conjugate vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03632720 ↗
Known as	Pneumococcal 7 valent conjugate vaccine	“One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.” NCT00667602 ↗ 3 “Pneumococcal 7 valent conjugate vaccine (Prevenar®)” NCT00219401 ↗ NCT00474526 ↗ NCT00257127 ↗
Known as	Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01049035 ↗
Known as	Pneumococcal conjugate vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01437267 ↗ 5 NCT01402245 ↗ NCT03109600 ↗ NCT00197821 ↗ NCT01229176 ↗ NCT00622843 ↗
Known as	Pneumococcal Conjugate Vaccine (PCV)	“Prevnar- Pneumococcal Conjugate Vaccine (PCV)” NCT01245673 ↗
Known as	Pneumococcal conjugate vaccine (PCV13)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04745559 ↗
Known as	Pneumococcal Conjugate Vaccine 13 (PCV13)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01527591 ↗
Known as	pneumococcal conjugated vaccine 13 (PCV13)	“pneumococcal conjugated vaccine 13 (PCV13)” NCT07154537 ↗
Known as	Pneumococcal vaccine	“The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).” NCT01597492 ↗ 10 “Pneumococcal (vaccine)” NCT00338351 ↗ NCT00721396 ↗ NCT01339000 ↗ NCT01411241 ↗ NCT00323557 ↗ NCT00239694 ↗ NCT00327522 ↗ NCT07242092 ↗ NCT05155579 ↗ NCT04515147 ↗
Known as	Pneumococcal vaccine (13-valent)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547271 ↗
Known as	Prevenar	“The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00474539 ↗ 43 “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366899 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00368966 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366678 ↗ “Multicentre Immune Memory Study in Healthy Children Following a 3 Dose Primary Vaccination With Prevenar or GSK Biologicals' Pneumococcal Conjugate Vaccine Via the...” NCT00333450 ↗ “Invasive pneumococcal disease rates have declined since immunization with 7-valent pneumococcal conjugate vaccine (PCV7) (Prevenar/Prevnar [Wyeth Pharmaceuticals, Philadelphia,...” PMID 20435707 ↗ May 2010 “Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM” NCT00562939 ↗ “To Evaluate the Humoral Immune Response to a Conjugated Pneumococcus Vaccine 7-Valent (Prevenar®) in Children From High Risk Groups.” NCT00581620 ↗ “a 13-valent conjugate vaccine (Prevenar®) and a 23-valent polysaccharide vaccine (Pneumovax®)” NCT04214444 ↗ “To describe the immunogenicity of a booster dose of Prevenar™ given at 12 to 24 months.” NCT01444781 ↗ NCT00843895 ↗ NCT02240888 ↗ NCT00343421 ↗ NCT00679159 ↗ NCT00624819 ↗ NCT00276107 ↗ NCT00463437 ↗ NCT00547248 ↗ NCT00871338 ↗ NCT00344318 ↗ NCT00907777 ↗ NCT00370396 ↗ NCT00586612 ↗ NCT00836641 ↗ NCT00294294 ↗ NCT00999739 ↗ NCT00581035 ↗ NCT00828997 ↗ NCT00169728 ↗ NCT00656409 ↗ NCT00127855 ↗ NCT00652951 ↗ NCT00611663 ↗ NCT00680914 ↗ NCT00911144 ↗ NCT01003418 ↗ NCT00134719 ↗ NCT00219401 ↗ NCT00900978 ↗ NCT01263210 ↗ NCT01983540 ↗ NCT00657709 ↗ NCT01193582 ↗ NCT01414504 ↗
Known as	Prevenar (heptavalent conjugated pneumococcal vaccine)	“Prevenar (heptavalent conjugated pneumococcal vaccine)” NCT00999739 ↗
Known as	Prevenar 7	“heptavalent pneumococcal conjugate vaccine (Prevenar 7; PCV7) and non-vaccinated individually matched arthritis patients.” PMID 25656734 ↗ Feb 2015
Known as	Prevenar---13, Pfizer Ltd.	“Prevenar---13®, Pfizer Ltd.” NCT02002156 ↗
Known as	Prevenar/Prevenar	“The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal...” NCT00366340 ↗
Known as	Prevenar13	“Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,...” NCT03619252 ↗ 64 “New recommendations have just been issued by the HSCP advising immunocompromised patients to follow a vaccination plan combining one dose of Prevenar13® followed by one dose of...” NCT02255227 ↗ “The purpose of this trial is to investigate in detail the kinetics of the immune response to Prevenar-13, a pneumococcal conjugate vaccine, compared to Pneumovax-II, a...” NCT01432158 ↗ “Currently in the UK, 3 doses of a vaccine called Prevenar 13 (PCV-13), which contains 13 pneumococcal serotypes attached to a carrier protein called CRM197, are given to...” NCT01443416 ↗ “One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.” NCT04875819 ↗ “Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm.” NCT02123433 ↗ “Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.” NCT02173704 ↗ “the investigators would like to study the use of an alternative vaccine against pneumococcus called Prevenar13 (or pCV13).” NCT01939522 ↗ “Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age” NCT01218451 ↗ “Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.” NCT02547493 ↗ “Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0” NCT01926860 ↗ “by the conjugated vaccine Prevenar13 ® in patients suffered from rheumatoid polyarthritis” NCT01942174 ↗ “13-valent pneumococcal conjugate vaccine (Prevenar13)” PMID 28081972 ↗ Jan 2017 “Subjects will be vaccinated once with Prevenar13.” NCT06202703 ↗ “PCV pneumococcal vaccine (Prevenar 13®)” NCT03095326 ↗ “Prevenar13® conjugate vaccine (PCV)” NCT02052154 ↗ “GCflu and Prevenar-13” NCT02582047 ↗ “PCV13(Prevenar 13)” NCT06608199 ↗ NCT01839188 ↗ NCT02274415 ↗ NCT01839175 ↗ NCT01090453 ↗ NCT01641133 ↗ NCT04830358 ↗ NCT01939158 ↗ NCT04031846 ↗ NCT02787863 ↗ NCT01947010 ↗ NCT07286370 ↗ NCT01480258 ↗ NCT01439360 ↗ NCT04460235 ↗ NCT03896477 ↗ NCT02308540 ↗ NCT01453998 ↗ NCT01735084 ↗ NCT03838497 ↗ NCT01174849 ↗ NCT04016714 ↗ NCT02215863 ↗ NCT01781871 ↗ NCT03565159 ↗ NCT01926860 ↗ NCT03873727 ↗ NCT02255227 ↗ NCT05759520 ↗ NCT05667740 ↗ NCT01432158 ↗ NCT05982314 ↗ NCT01204658 ↗ NCT03207750 ↗ NCT01619462 ↗ NCT02279589 ↗ NCT07593924 ↗ NCT02640703 ↗ NCT01341639 ↗ NCT02628886 ↗ NCT01942174 ↗ NCT02002156 ↗ NCT06550830 ↗ NCT03439657 ↗ NCT01847781 ↗ NCT01248884 ↗ NCT01892618 ↗ NCT02918708 ↗
Known as	PrevenarTM	“Pneumococcal 7-Valent Conjugate Vaccine [DIPHTHERIA CRM197 PROTEIN] (PrevenarTM) in Healthy Infants” NCT00488826 ↗
Known as	Prevnar	“7-Valent pneumococcal conjugate vaccine (PCV7 [Prevnar, Wyeth Pharmaceuticals Inc, Philadelphia, PA], serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) is effective in preventing...” PMID 20732948 ↗ Aug 2010 44 “Invasive pneumococcal disease rates have declined since immunization with 7-valent pneumococcal conjugate vaccine (PCV7) (Prevenar/Prevnar [Wyeth Pharmaceuticals, Philadelphia,...” PMID 20435707 ↗ May 2010 “Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)” NCT00569309 ↗ “Pneumococcal Conjugate Vaccine (Prevnar; Wyeth) With Pneumococcal Polysaccharide Vaccine (23-valent) and Tetanus/Diphtheria Vaccine” NCT00164411 ↗ “Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion” NCT00834665 ↗ “Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants” NCT00401531 ↗ “A 7-valent pneumococcal conjugate vaccine (PCV-7) was licensed in 2000 (Prevnar™, Wyeth Lederle Vaccines)” NCT00153543 ↗ “In Thailand, 7 - valent PCV (Prevnar® ) was available in 2003.” NCT01135082 ↗ “heptavalent pneumococcal vaccine (PCV7; Prevnar(®), Pfizer)” PMID 25424793 ↗ 2014 “pneumococcal 13-valent conjugate vaccine (Prevnar)” NCT03942328 ↗ “Biological: PCV7, Prevnar®” NCT00169234 ↗ “Prevnar® vaccine” NCT01098474 ↗ “PREVNAR™” NCT00109343 ↗ NCT00729001 ↗ NCT00137605 ↗ NCT00772928 ↗ NCT00578175 ↗ NCT01312389 ↗ NCT00023504 ↗ NCT00143780 ↗ NCT00323622 ↗ NCT00861744 ↗ NCT06562790 ↗ NCT00371878 ↗ NCT00197002 ↗ NCT06800261 ↗ NCT00289783 ↗ NCT00129129 ↗ NCT07300644 ↗ NCT01041573 ↗ NCT01215175 ↗ NCT01307449 ↗ NCT00457977 ↗ NCT00312858 ↗ NCT00152802 ↗ NCT01098474 ↗ NCT00109343 ↗ NCT00345683 ↗ NCT00170612 ↗ NCT00390130 ↗ NCT06617715 ↗ NCT00594347 ↗ NCT01245673 ↗ NCT00304382 ↗ NCT00262002 ↗
Known as	Prevnar 20	“All participants will receive a single intramuscular dose (0.5 mL) of PCV20 (Prevnar 20®, Pfizer), administered into the deltoid muscle at baseline (Day 0).” NCT07242092 ↗
Known as	vaccine-13vPnC	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01432262 ↗
Modality	Vaccine	“using Pneumococcal vaccine immunization” NCT00023504 ↗
Route	Intramuscular	“0.5-mL intramuscular injection” NCT00109343 ↗